510(k) device
EyeArt v2.2.0
Eyenuk, Inc. · Diabetic Retinopathy Detection Device (PIB, Class II) · First FDA decision Jun 16, 2023, newest Jun 16, 2023DiabetesMacular degeneration and retinal disease
Last checked: Nov 19, 2026Source: FDA, CMS, ClinicalTrials.gov, PubMed
FDA decisions
1
510(k) pathway
Device trials
0
Naming "EyeArt v2.2.0"
MAUDE reports
0
Brand "EyeArt v2.2.0", since 2015
PubMed studies
0
Mentioning "EyeArt v2.2.0"
AI summary across all sources
Written by AI from the FDA, CMS, ClinicalTrials.gov, MAUDE and PubMed data on this page, plus web searches for payment facts.
Product review deck
A slide deck reviewing EyeArt v2.2.0
About ten slides on the technology, clinical evidence, regulatory history and commercialization, built with AI from the data on this page and web research, with sources. Download it as PowerPoint to edit or as PDF to share.
- Executive summary and key facts
- Technology
- Clinical evidence and trials
- Regulatory history and safety
- Reimbursement, market and competition
- Risks, outlook and sources
AI-written from public data and may contain mistakes. Check each fact against its source before relying on it. Not investment, legal, reimbursement or medical advice.
FDA decisions
The newest 1 of 1 decisions filed under this name.
- EyeArt v2.2.0510(k)
K223357 · Decided Jun 16, 2023 · 226 days after receipt
Device type: Diabetic Retinopathy Detection Device (PIB) · Ophthalmology
Medicare coverage
National and local coverage documents whose titles match this device or its device type. Payment add-ons (NTAP, pass-through, TCET) and likely codes are covered in the summary above.
No Medicare coverage document has a title matching this device or device type. Many devices are paid under existing codes without one.
Clinical trials
Device studies on ClinicalTrials.gov that name "EyeArt v2.2.0", any status and sponsor, newest update first.
No registered device study names "EyeArt v2.2.0".
Adverse event reports (MAUDE)
Reports received since 2015 naming the brand "EyeArt v2.2.0", and for the whole product code for context.
This brand
0 reports: 0 malfunction, 0 injury, 0 death
Whole product code PIB
1 reports: 0 malfunction, 1 injury, 0 death
Newest reports for this brand
No MAUDE reports name this brand.
Recalls
From FDA's recall database. FDA lists each recalled product separately, so one recall can appear several times. A recall is often a correction or a labeling change, not a removal from the market.
No recall in FDA's data is linked to these FDA numbers.
Published research
The most relevant PubMed records for "EyeArt v2.2.0"[tiab]. The summary above synthesizes these.
No PubMed record mentions this device by name.
Other devices of this type
Also filed under product code PIB.
- Aeye-DsAeye Health, Inc. · 510(k) 2024
- iPredict-DRiHealthscreen, Inc. · 510(k) 2026
- IDx-DR v2.3Digital Diagnostics, Inc. · 510(k) 2022
- IDx-DRDigital Diagnostics, Inc. · 510(k) 2021
- EyeArtEyenuk, Inc. · 510(k) 2020
- IDx-DRIdx, LLC · De Novo 2018
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.